Track 1 — International IP Risks: Effectively Managing a Global Pharmaceutical IP Litigation Strategy

• Assessing common international business scenarios encountered by both brand name and generic manufacturers which lead to patent disputes
• Identifying potential safe-harbor concerns related to foreign manufacturers and finishers
• Building and managing a winning global litigation team
• Understanding the importance of aligning legal and business functions for global patent litigation planning
• Exploring matters of international trade and impacting the value of pharmaceutical patents

Track 2 — Joint Defense Groups: A Risk Benefit Analysis for the Hatch-Waxman Practitioner

• Evaluating the benefits and detriments of joint defense groups in PIV disputes
• Maximizing efficiency and minimizing risk by protecting joint legal interests resourcefully
• Devising brand name strategies for addressing litigation with joint defense groups
• Establishing clear leadership at the outset to simplify future occurrences
• Understanding when and how many consulting firms to utilize toward avoiding too many cooks in the kitchen

Track 3 — Closed Door Executive Meeting with ACI’S Hatch-Waxman Series Advisory Board

Limited to 24 participants (12 brand; 12 generic) by invitation- only, this unique, interactive discussion will provide an exclusive and intimate networking and benchmarking opportunity that will shed light on the expectations of in-house counsel from their law firm partners.

It is also a vehicle for other in-house counsel to benchmark their current “3C’s” strategies with those of the Board.

• “Cost”, will offer insights on the monitoring of legal spend and balancing a budget.
• “Competency”, will provide best practices for overcoming talent limitations with demonstrable advice.
• “Communication”, will engage attendees in the art of communicating value and fostering collaboration between corporate legal counsel and outside counsel.